Business NewsPR NewsWire • Harvard bioengineers' biomaterial-based cancer immunotherapies to be developed by Novartis

Harvard bioengineers' biomaterial-based cancer immunotherapies to be developed by Novartis

Harvard bioengineers' biomaterial-based cancer immunotherapies to be developed by Novartis

BOSTON, March 20, 2018 /PRNewswire-USNewswire/ -- The Wyss Institute for Biologically Inspired Engineering at Harvard University and the Harvard John A. Paulson School of Engineering and Applied Sciences (SEAS) announced today that Novartis will have access to commercially develop their...

View More : https://www.prnewswire.com/news-releases/harvard-bioengineers-biomaterial-based-cancer-immunotherapies-to-be-developed-b...
Releted News by prnewswire
Harvard bioengineers' biomaterial-based cancer immunotherapies to be developed by Novartis
Brammer Bio Expands Leadership Team for Commercial Readiness
redPanda Software wins Global Award for Customer Value Leader in Enterprise Software for Retailers